GUIDANCE - Unknown Company - FDA Guidance: Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry | Global Key Solutions

GUIDANCE - Unknown Company - FDA Guidance: Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry | Global Key Solutions | Global Key Solutions